NCT03335852View on ClinicalTrials.gov

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

October 8, 2018

Study Completion Date

October 8, 2018

Conditions
Macular Degeneration
Interventions
DRUG

Abicipar pegol

Abicipar pegol 2 mg administered to the study eye by intravitreal injection

Trial Locations (5)

737-0029

Kimura Eye and Internal Medicine Hospital, Kure

543-0027

Musashi Dream Clinic, Tennouji-ku

111-0051

Takeuchi Eye Clinic, Taito-ku

812-0025

Souseikai Hakata Clinic, Fukuoka

960-1295

Fukushima Medical University Hospital, Fukushima

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03335852 - Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD | Biotech Hunter | Biotech Hunter